Armenia vs Morocco: Average cost of drugs for extensively drug-resistant tuberculosis
Armenia
4,190 constant 2022 US$
in 2024
Morocco
4,500 constant 2022 US$
in 2024
Armenia rank
16th
Morocco rank
14th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Armenia
- Morocco
How they compare
Morocco currently reports 4,500 constant 2022 US$ against 4,190 constant 2022 US$ in Armenia, a difference of 310 constant 2022 US$.
That makes Morocco's figure about 1.1 times Armenia's.
The two have swapped places 2 times across 6 shared years of data; in 2019 it was Morocco ahead.
Armenia ranks 16th and Morocco ranks 14th of 56 countries.
Across the 2 decades both report, Armenia averaged higher in 1 and Morocco in 1.
Head to head by decade
| Decade | Armenia | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,900 constant 2022 US$ | 6,800 constant 2022 US$ | 1,900 constant 2022 US$ | Morocco |
| 2020s | 5,178 constant 2022 US$ | 3,909 constant 2022 US$ | 1,269 constant 2022 US$ | Armenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Armenia or Morocco?
- Morocco, at 4,500 constant 2022 US$ against 4,190 constant 2022 US$ in Armenia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Armenia and Morocco?
- 310 constant 2022 US$, with Morocco ahead.
- How many years of comparable data are there for Armenia and Morocco?
- 6 years are reported by both, from 2019 to 2024.
- How do Armenia and Morocco rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Armenia ranks 16th and Morocco ranks 14th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.